Y. Komada et al., A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy, EUR J CANC, 35(7), 1999, pp. 1095-1101
This randomised study was performed to assess the anti-emetic efficacy and
tolerability of two-dose regimens of granisetron in children with leukaemia
. 49 children with leukaemia were treated with three consecutive courses of
high-dose methotrexate or cytarabine regimen. During the first course, pat
ients were evaluated regarding the emetogenicity of each regimen. They were
randomised in a crossover manner to receive 20 or 40 mu g/kg of granisetro
n before the second and third course of chemotherapy. Neither emesis nor se
vere appetite loss were observed in over 80% of patients within the first 2
4h in all treatment groups. There was no significant difference in the anti
-emetic efficacy between the two-dose regimens of granisetron. However, com
plete protection was achieved less frequently on days 2 and 3. Older childr
en and girls appeared to be less well protected. No adverse events attribut
able to granisetron were observed. Granisetron dose regimens of 20 and 40 m
u g/kg are, comparably, well tolerated and effective in controlling chemoth
erapy-induced emesis in the first 24h, though this protection fails thereaf
ter, particularly in older patients and girls (C) 1999 Elsevier Science Ltd
. All rights reserved.